Wet AMD

>

Latest News

FDA issues CRL for Regeneron's aflibercept 8 mg (Eylea HD) sBLA
FDA issues CRL for Regeneron's aflibercept 8 mg (Eylea HD) sBLA

April 21st 2025

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

FDA accepts Outlook Therapeutics' updated biologics license application for ONS-5010 to treat wet AMD
FDA accepts Outlook Therapeutics' updated biologics license application for ONS-5010 to treat wet AMD

April 9th 2025

Seville, Spain, and the Giralda of Seville, in June 2018. Image credit: ©Julián Maldonado – stock.adobe.com
The Congress on Controversies in Ophthalmology (COPHy) highlights debates in surgical, medical retina

April 4th 2025

Ocular Therapeutix accelerates timelines for SOL-1 Phase 3 trial of Axpaxli for wet AMD
Ocular Therapeutix accelerates timelines for SOL-1 Phase 3 trial of Axpaxli for wet AMD

October 19th 2024

Clearside Biomedical releases positive topline results from ODYSSEY Phase 2b Trial of suprachoroidal axitinib injectable suspension in wet AMD
Clearside Biomedical releases positive topline results from ODYSSEY Phase 2b Trial of suprachoroidal axitinib injectable suspension in wet AMD

October 9th 2024

Video Series
Video Interviews
Podcasts
John Kitchens, MD, is joined by Peter Kaiser, MD, to discuss higher molar dose and its translation into clinical practice

More News

© 2025 MJH Life Sciences

All rights reserved.